Health · Pharma & Biotech · 2 hrs ago
FDA approves injectable gefurulimab for some adults with myasthenia gravis
The FDA approved injectable gefurulimab, sold as Klygefa, on Friday.
It is for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies.
Myasthenia gravis is the condition named in the approval, and the authorization covers a specific group of adults.
Gefurulimab is a dual-binding nanobody.
It blocks activation of complement component 5, known as C5.
The available information does not say when the treatment will become available or describe next steps.
The FDA approved injectable gefurulimab, marketed as Klygefa, to treat generalized myasthenia gravis in some adults.
The approval was reported on Friday, November 13, 2026.
Gefurulimab is a dual-binding nanobody that blocks activation of complement component 5.
The article text identifies adults who are anti-acetylcholine receptor (AChR), but the eligibility details are cut off.
- Who
- Adults with generalized myasthenia gravis; the article’s eligibility details are incomplete.
- What
- The FDA approved injectable gefurulimab, marketed as Klygefa, for treatment.
- When
- Friday, November 13, 2026.
- Where
- Not stated.
- Why
- It is approved to treat generalized myasthenia gravis; it blocks complement component 5 activation.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Gefurulimab (Klygefa)
- Form
- Injectable
- Approval
- FDA approval reported November 13, 2026
- Mechanism
- Dual-binding nanobody that blocks complement component 5 activation
- Condition
- Generalized myasthenia gravis in adults